摘要
目的：为探讨ＤＢＡ／２小鼠脾淋巴细胞诱生的抗ＣＤ３单克隆抗体（单抗）激活的杀伤细胞（ＣＤ３ＡＫ细胞）过继输入及联合化疗和生物反应调节剂对小鼠白血病的治疗作用。方法：将Ｐ３８８细胞移植到ＤＢＡ／２小鼠腹腔建立白血病模型，用抗ＣＤ３单抗和小剂量重组白细胞介素２（ｒＩＬ－２）从小鼠脾细胞中诱生ＣＤ３ＡＫ细胞。检测淋巴细胞转化率、ＮＫ细胞活性和脾淋巴细胞ＩＬ－２诱生水平以及荷瘤鼠生存期。结果：小鼠接种Ｐ３８８细胞后细胞免疫功能（淋巴细胞转化率、ＮＫ活性和ＩＬ－２水平）明显减低。转输ＣＤ３ＡＫ细胞和小剂量ｒＩＬ－２，小鼠生存期延长（４５．１９％），细胞免疫功能显著增强；单纯化疗可以延长小鼠生存期（２９．９０％），但却使免疫功能低下的荷瘤鼠的Ｔ细胞和ＮＫ细胞功能进一步降低，与ＣＤ３ＡＫ细胞转输联合可阻止化疗所致的免疫功能的降低，生存期进一步延长（５９．４５％），并有２５％的小鼠长期存活；硒酸酯多糖与ＣＤ３ＡＫ细胞或ＣＤ３ＡＫ细胞＋化疗联合应用治疗效果最佳，１２．５％～７５．０％小鼠长期存活，且体内未发现有白血病细胞存在。结论：硒酸酯多糖是一种实用而有效的生物反应调节剂，肿瘤杀伤效应细胞＋化疗＋生物反应调节剂方案是一种白?
Objective:To study the antileukemia efficacy of a combination of adoptive transfer of CD 3AK cells, cyclophosphamide(CTX) , and kappa selenocarrageenan(KSC)in P 388 leukemic mice.Methods:CD 3AK cells in normal DBA/2 murine splenocytes were induced with anti CD 3 antibody and low dose recombinant interleukin 2 (rIL 2).The P 388 murine leukemia model was induced by i.p.injection of P 388 cells into normal DBA/2 mice.The tumor bearing mice were administrated with adoptively transferred CD 3AK Cells and/or CTX and/or KSC.Results:After tumor inoculation ,the cellular immune function of P 388 bearing mice was supressed markedly.Adoptive transfer of CD 3AK cells with low dose rIL 2 into the P 388 mice significantly enhanced the splenocyte proliferation (SP) induced by Con A ,the NK cell activity and the splenocytic IL 2 production and prolonged their survival(45.19%);CTX(200 mg/kg) alone prolonged the survival of P 388 bearing mice(29.90%),but further decreased the immunodeficiency ; combination of CTX and CD 3AK passive transfer could prevent the reduction of SP,NK activity and IL 2 production in the leukemic mice and prolonged the survival(59.45%),combination of KSC and adoptively transfected CD 3AK cells and/or CTX had a much better therapeutic efficacy for P 388 murine leukemia,12.50%～75.00% of the leukemic mice were cured.Conclusion:KSC is a hopeful biological response modifier in cancer biotherapy,and tumor killing effector cells and chemotherapy plus BRM might be a promising candidate for human leukemia biotherapy.
出处
《中华血液学杂志》
CAS
CSCD
北大核心
1997年第5期243-246,共4页
Chinese Journal of Hematology
关键词
CD3AK细胞
环磷酰胺
硒酸酯多糖
白血病
CD 3AK cells Cyclophosphamide Kappa selenocarrageenan Leukemia,experimental Biotherapy
